Member Info for thehierarchy

An interesting read on the HTC conference VRE supported which provides a glimpse of why HTC was keen to invest!
I particularly like the following comment which clearly opens the door for VRE...
On stage at V2EC, a new strategic partnership between HTC and IVRE was announced, allowing HTC to distribute the ENGAGE platform globally. The ENGAGE VR software is already available for download on VIVEPORT.
https://www.prnewswire.com/news-releases/htc-conducts-its-first-virtual-vive-ecosystem-conference-vec-fully-in-vr-allowing-global-attendees-to-join-virtual-sessions-301026602.html

Results aren't going to be anything other than a small loss/breakeven at best.
But, market cap of £3.8m against net cash of more than £2m and a property asset ripe for disposal valued at £2.4m then the technology is valued at nil. Obviously a bombed out sector but GTC is diversifying and enjoys some decent recurring revenue, so at the current price it looks extremely cheap. Business Growth Fund and Alto Invest were adding last year as IP Group exited GTC along with much of its other investments. Looks a prime target for a larger player to take out.

Falklandinvestor, I wouldn't count on a retained dividend, the cover was already down at the bottom and that was before the lock down.

I think the interesting and positive aspect with IHC moving forward is that increasingly it is becoming more than just a distributor. And with approaching 50% of revenues now generated from its own brands along with 12% organic growth achieved the company looks to be in a decent spot.
Looks more like a slow burner which won't attract the in and out brigade, but one that could/should be very rewarding over the medium /longer term.

It is so much more than this virus.
Proven to be effective in the fight against numerous diseases and assist in identifying those most at risk.
Preventative measure and personal tailored medicine is the way forward and OBD has a very good key to unlock growth and value for shareholders.

Who knows could be possible!
Worth looking back at the comments from the founder and head of GI Capital eighteen months back when they made the £10m investment.

Jeffrey Li, founder and chief executive of GL Capital Group, added: “GL’s investment strategy is founded on identifying market-leading companies with innovative technologies or products that have a robust scientific basis, strong competitive barriers and promising growth potential. Following extensive due diligence, we are delighted to be making an investment in OBD.
Jeffrey Li, founder and chief executive of GL Capital Group, added: “GL’s investment strategy is founded on identifying market-leading companies with innovative technologies or products that have a robust scientific basis, strong competitive barriers and promising growth potential. Following extensive due diligence, we are delighted to be making an investment in OBD.

“We have been following OBD‘s progress for a considerable period of time and clearly see the company at the forefront of personalized medicine on a global basis.”

Me too Napoleon. The US is where personalised and targeted medicine is really being targeted so I would say OBD is placing an emphasis on that which could bring some very lucraive tie-ups. That said, it is already aligned to some big named Pharma players over there.

Hi there, what is the relevance to OBD with the Pfizer reference?

Blood test though, not as suitable for mass roll out.

Surely, this would be fast tracked, after all it is a device is it not.

I would be surprised and disappointed if this retraced further on the prospects, unless they are not achievable, which I think they are. On a forward PER, the shares trade on a figure little more than 7, which is usually attributed to debt laden stocks.
That isn't the case here and looking at the expected numbers and prospects the market cap looks very modest to me.
Obviously the sluggish consumer markets weigh, but that appears to be more than factored in.
Clearly a seller has been about, but perhaps that is near to being cleared which would pave the way for a reversal.

Also took a position here recently, may be of interest to others holding or looking.
https://www.cambridge-news.co.uk/business/martin-flitton-shares-views-investment-16704414

https://www.cambridge-news.co.uk/frontier-developments-jurassic-world-games-16026660

https://www.cambridge-news.co.uk/business/sawston-business-rapid-growth-getbusy-15778013

https://www.cambridge-news.co.uk/business/private-punter-investing-in-sosandar-15673317

Looks like First Point over the 30% so mandatory bid must follow if the case or reverse in.

Presumably if NP goes for a full bid, it will no doubt be to make use of the listing.
The NAK quote alone must be worth circa half a million, then you have a business that has returned to profit and is capable of delivering improved NFI without further investment.
Plus, given SH paid 1.8p for its stake, any bid tabled would surely have to be north of 2.5p to have a chance of acceptance.
Even that would seem cheap and it is most likely that SH aren't in the market for selling given the changes they have implemented, perhaps more likely to table a bid of its own.
Interesting times here and the upside would appear to far outweigh the negatives.

Excellent results showing the new team has cut, culled and turned around.
A work in progress obviously, but prospects look increasingly positive.
Net fee income equaled that on the previous period but with 20% plus less head.

Dead wood has been and continues to be cleared out, paving the way for more proactive players.
As it stands, this could be doing £600k plus pre-tax next year, quite possibly more with operational support from its key shareholders Sheffield Haworth and First Point. The market cap of circa £1.2m is paltry and the shares are looking cheap.

Don't get bogged down by turnover, it's all about net fee income and that is currently circa £5m-peanuts!
That said, things continue to move here and who has sold Sheffield and if so, which one?

Is it going private/RT or something else!
Interesting times.

Obvious thought would be Sheffield Hayworth. But, from my understanding NAK is effectively in a closed period with the interim results out later this month, so timing would be unusual. Equally possible I suppose is that it could be the former Directors two of whom collectively hold 26m. Given they no longer have an active role in the company, they may have decided to sell out. As you say Skier1, an RNS should provide some clarity.